View EPIDYS
Pivotal Trial
DUVYZAT was studied in the
largest DMD clinical trial to date.1
Request a visit
Fill out the form below to request a visit from ITF Therapeutics.
Note: this request form is for healthcare providers only. If you are an individual with DMD, please sign up for updates using the form on the home page.
*Required field.
View EPIDYS
NOW AVAILABLE
Check back for updates on DUVYZAT availability and register for more information below.
Resources
Patient Start Form
Enroll your patients in the ITF ARC patient support program with this downloadable PDF.
Healthcare Provider Webinar
Explore insights from the HCP community update webinar sponsored by ITF Therapeutics.
Learn from DMD experts about
- The cascade of pathologic changes in DMD, including chronic inflammation, impaired muscle regeneration, and increased fibrogenesis and adipogenesis
- The hypothesized mechanism of action of DUVYZAT
- DUVYZAT efficacy and safety data from the largest DMD phase 3 trial to date and how DUVYZAT can be integrated into your clinical practice
Sign Up for Updates on DUVYZAT
*Required field.
FDA, Food and Drug Administration.
References: 1. Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al; EPIDYS Study Group. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre,
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024;23(4):393-403. 2. Italfarmaco Receives FDA Approval for DuvyzatTM (givinostat) in Duchenne
Muscular Dystrophy. [Press release]. Accessed June 10, 2024. Available at: https://itftherapeutics.com/documents/Italfarmaco_receives_FDA_approval.pdf
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024;23(4):393-403. 2. Italfarmaco Receives FDA Approval for DuvyzatTM (givinostat) in Duchenne
Muscular Dystrophy. [Press release]. Accessed June 10, 2024. Available at: https://itftherapeutics.com/documents/Italfarmaco_receives_FDA_approval.pdf
Indication and Important Safety Information
What is DUVYZAT?
DUVYZAT is a prescription medicine that is used for the treatment of Duchenne muscular dystrophy (DMD) in people 6 years of age and older.
Indication and Important Safety Information
What is DUVYZAT?
DUVYZAT is a prescription medicine that is used for the treatment of Duchenne muscular dystrophy (DMD) in people 6 years of age and older.
It is not known if DUVYZAT is safe and effective in children under 6 years of age.
Important Safety InformationWhat is the most important information I should know about DUVYZAT?
- Low platelet counts in your blood (thrombocytopenia). Platelets are important for blood clotting, and a decrease in their numbers can lead to an increased risk of bleeding or bruising. Your healthcare provider will check your blood count before you start DUVYZAT and regularly during treatment for any signs of thrombocytopenia. Call your healthcare provider right away if you notice any unusual bleeding or small red or purple spots on the skin called petechiae. Your healthcare provider may change your dose of DUVYZAT if your blood platelet counts continue to be low or may stop your treatment with DUVYZAT.
- Increased levels of fat (triglycerides) in your blood. You may not have any symptoms, so your healthcare provider will do blood tests before you start DUVYZAT and regularly during treatment to check your triglyceride levels. Your healthcare provider may change your dose of DUVYZAT if your triglyceride levels continue to be high or may stop your treatment with DUVYZAT.
- Frequent watery loose stools (diarrhea) and vomiting. DUVYZAT can cause vomiting and moderate to severe diarrhea. If diarrhea occurs, you should keep track of the frequency and severity of your diarrhea symptoms, drink plenty of fluids, and contact your healthcare provider. Your healthcare provider may change your dose of DUVYZAT if the diarrhea cannot be managed or does not go away. Your healthcare provider may also stop your treatment with DUVYZAT.
Before taking DUVYZAT, tell your healthcare provider about all of your medical conditions, including if you:
- have any heart problems or if you take any medicines that could increase your chance for irregular heart rhythms.
- have any bleeding problems.
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Taking DUVYZAT with certain other medicines may affect each other. Taking DUVYZAT with other medicines can cause serious side effects. Do not start or stop other medicines without talking to your healthcare provider.
DUVYZAT can cause serious side effects, including:
- See “What is the most important information I should know about DUVYZAT?”
- Changes in the electrical activity of your heart called QT Prolongation. QT Prolongation can increase the risk of developing a type of irregular heart rhythm known as Torsades de Pointes. Call your healthcare provider right away if you feel faint, have an irregular heartbeat, feel dizzy, or lose consciousness.
The most common side effects of DUVYZAT included diarrhea, nausea, vomiting, stomach pain, low platelet counts in the blood, increased fat level in the blood, and fever.
These are not all of the possible side effects of DUVYZAT. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please see full Prescribing Information and Medication Guide.